Immutep (ASX:IMM) received roughly AU$3.6 million in research and development-related tax incentives from the French government, according to a Tuesday filing with the Australian bourse.
The ASX-listed biotechnology company received the payment through its subsidiary, Immutep SAS. Under the French government's Research Tax Credit scheme, French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure, the filing stated.
Immutep said it will use the funds for the global clinical development of eftilagimod alpha and IMP761.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。